International Nuclear Medicine Consensus on the Clinical Use of Amyloid Positron Emission Tomography in Alzheimer’s Disease  

作　　者：Mei Tian Chuantao Zuo Ali Cahid Civelek Ignasi Carrio Yasuyoshi Watanabe Keon Wook Kang Koji Murakami Valentina Garibotto John OPrior Henryk Barthel Yihui Guan Jiaying Lu Rui Zhou Chentao Jin Shuang Wu Xiaohui Zhang Yan Zhong Hong Zhang Molecular Imaging-Based Precision Medicine Task Group of A3(China-Japan-Korea)Foresight Program 

机构地区：[1]PET Center,Huashan Hospital,Fudan University,Shanghai 200235,China [2]Human Phenome Institute,Fudan University,Shanghai 201203,China [3]Department of Nuclear Medicine and PET Center,The Second Affiliated Hospital of Zhejiang University School of Medicine,Hangzhou 310009,China [4]National Center for Neurological Disorders and National Clinical Research Center for Aging and Medicine,Huashan Hospital,Fudan University,Shanghai 200040,China [5]Department of Radiology and Radiological Science,Division of Nuclear Medicine and Molecular Imaging,Johns Hopkins Medicine,Baltimore 21287,USA [6]Department of Nuclear Medicine,Hospital Sant Pau,Autonomous University of Barcelona,Barcelona 08025,Spain [7]Laboratory for Pathophysiological and Health Science,RIKEN Center for Biosystems Dynamics Research,Kobe,Hyogo 650‑0047,Japan [8]Department of Nuclear Medicine,Seoul National University College of Medicine,Seoul 03080,Korea [9]Department of Radiology,Juntendo University Hospital,Tokyo 113‑8431,Japan [10]Diagnostic Department,University Hospitals of Geneva and NIMTlab,University of Geneva,Geneva 1205,Switzerland [11]Department of Nuclear Medicine and Molecular Imaging,Lausanne University Hospital,Lausanne 1011,Switzerland [12]Department of Nuclear Medicine,Leipzig University Medical Center,Leipzig 04103,Germany [13]Key Laboratory of Medical Molecular Imaging of Zhejiang Province,Hangzhou 310009,China [14]The College of Biomedical Engineering and Instrument Science of Zhejiang University,Hangzhou 310007,China [15]Key Laboratory for Biomedical Engineering of Ministry of Education,Zhejiang University,Hangzhou 310007,China [16]不详

出　　处：《Phenomics》2023年第4期375-389,共15页表型组学（英文）

基　　金：This study was partially sponsored by the National Natural Science Foundation of China(NSFC)(81761148029,81725009,82030049,82021002,81971641);Ministry of Science and Technology of China(MOST)(2021YFA110004500,2021YFE0108300);Clinical Research Plan of SHDC(SHDC2020CR1038B);Science and Technology Innovation 2030 Major Projects(2022ZD0211600);Swiss National Science Foundation(project nos.185028,188355,and 169876);National Research Foundation of Korea(NRF-2017K2A9A2A10013554).

摘　　要：Alzheimer’s disease(AD)is the main cause of dementia,with its diagnosis and management remaining challenging.Amyloid positron emission tomography(PET)has become increasingly important in medical practice for patients with AD.To integrate and update previous guidelines in the field,a task group of experts of several disciplines from multiple countries was assembled,and they revised and approved the content related to the application of amyloid PET in the medical settings of cognitively impaired individuals,focusing on clinical scenarios,patient preparation,administered activities,as well as image acquisition,processing,interpretation and reporting.In addition,expert opinions,practices,and protocols of prominent research institutions performing research on amyloid PET of dementia are integrated.With the increasing availability of amyloid PET imaging,a complete and standard pipeline for the entire examination process is essential for clinical practice.This international consensus and practice guideline will help to promote proper clinical use of amyloid PET imaging in patients with AD.

关 键 词：Positron emission tomography(PET) Alzheimer’s disease AMYLOID Brain imaging Expert consensus 

分 类 号：R749.16[医药卫生—神经病学与精神病学]